GlassScriptPhysician profile
Miguel Pedraza
NPI 1447980115
$1,057.13
in general payments reported to CMS, 2019-2025
21 companies · $35.18 in 2025
The $35.18 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $175 · 2023: $436 · 2024: $411 · 2025: $35.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $786 · Education: $96.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.60 |
| Education | $96.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $136.84 | 2022-2024 | Veltassa |
| Mallinckrodt Hospital Products INC. | $130.79 | 2022-2024 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $119.08 | 2023-2025 | |
| Aimmune Therapeutics, INC. | $99.53 | 2024 | |
| Fresenius USA Marketing, INC. | $92.63 | 2022-2025 | Velphoro, Velphoro |
| Amgen INC. | $89.49 | 2022-2023 | Tavneos |
| Regeneron Healthcare Solutions, INC. | $44.73 | 2022-2023 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $42.32 | 2022-2024 | Farxiga |
| Alexion Pharmaceuticals, INC. | $34.37 | 2023-2024 | Ultomiris |
| Abbvie INC. | $34.17 | 2023 | |
| Novartis Pharmaceuticals Corporation | $33.62 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $33.58 | 2022-2024 | Jynarque |
| Calliditas Therapeutics US INC. | $29.19 | 2023 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $20.15 | 2023 | Entyvio |
| Ultragenyx Pharmaceutical INC. | $19.37 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $19.36 | 2023 | Krystexxa |
| Grifols USA, LLC | $18.26 | 2023 | Prolastin-C Liquid |
| Lilly USA, LLC | $17.75 | 2023 | Mounjaro |
| Argenx US, INC. | $14.74 | 2024 | Vyvgart Hytrulo |
| Aurinia Pharma U.S., INC. | $14.01 | 2023 | Lupkynis |
| Scpharmaceuticals INC. | $13.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miguel Pedraza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.